Qiagen N.V. (QGEN)

NL — Healthcare Sector
Peers: NEOG  OLK  ACRS  SYNH  IQV  MEDP  ICLR  SHC  AKU  GTH  NTRA  NEO  GH 

Automate Your Wheel Strategy on QGEN

With Tiblio's Option Bot, you can configure your own wheel strategy including QGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol QGEN
  • Rev/Share 9.1716
  • Book/Share 15.6055
  • PB 2.8836
  • Debt/Equity 0.4133
  • CurrentRatio 3.3715
  • ROIC 0.0157

 

  • MktCap 9795825000.0
  • FreeCF/Share 2.3037
  • PFCF 19.4722
  • PE 104.9038
  • Debt/Assets 0.254
  • DivYield 0.0293
  • ROE 0.0269

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade QGEN Redburn Atlantic Buy Neutral -- -- April 4, 2025
Downgrade QGEN Robert W. Baird Outperform Neutral $52 $42 Feb. 19, 2025
Downgrade QGEN Morgan Stanley Overweight Equal Weight -- $48 Jan. 6, 2025
Upgrade QGEN Jefferies Hold Buy $42.5 $54 Dec. 10, 2024
Downgrade QGEN HSBC Securities Buy Hold -- $49 Oct. 17, 2024

News

QGEN Stock Might Gain Following New Partnership With ID Solutions
QGEN
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive

QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.

Read More
image for news QGEN Stock Might Gain Following New Partnership With ID Solutions
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
QGEN
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Here's Why Qiagen (QGEN) is a Strong Value Stock
QGEN
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Qiagen (QGEN) is a Strong Value Stock
Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript
QGEN
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Qiagen N.V. (NYSE:QGEN ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Doug Schenkel - Wolfe Research Patrick Donnelly - Citi Tycho Peterson - Jefferies Michael Ryskin - Bank of America Jan Koch - Deutsche Bank Jack Meehan - Nephron Research Dan Brennan - TD Cowen Catherine Schulte - Baird Matt Sykes - Goldman Sachs Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank …

Read More
image for news Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
QGEN
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.

Read More
image for news QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
QGEN
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
QGEN
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.47 per share a year ago.

Read More
image for news Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
QGEN
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Boar.

Read More
image for news QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics
QGEN
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral

Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Read More
image for news Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics
QGEN or RGEN: Which Is the Better Value Stock Right Now?
QGEN, RGEN
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?

Read More
image for news QGEN or RGEN: Which Is the Better Value Stock Right Now?
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
QGEN
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
QGEN
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
QGEN
Published: April 08, 2025 by: Business Wire
Sentiment: Neutral

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect.

Read More
image for news QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
QGEN
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral

Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below.

Read More
image for news Qiagen N.V.: Some Clarity Needed Before Buying The Dip

About Qiagen N.V. (QGEN)

  • IPO Date 1996-06-28
  • Website https://www.qiagen.com
  • Industry Medical - Diagnostics & Research
  • CEO Mr. Thierry Bernard
  • Employees 5700

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.